Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 37

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction

Briganti, Alberto, Salonia, Andrea, Gallina, Andrea, Saccà, Antonino, Montorsi, Piero, Rigatti, Patrizio, Montorsi, Francesco·2005·Nature Clinical Practice Urology
DOI 10.1038/ncpuro0186
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncpuro0186

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 62

  1. Saenz de Tejada I (2002) Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 14(Suppl 1): S6–S10 · DOI
  2. Kim N et al. (1993) Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J Clin Invest 91: 437–442 · DOI · Paper page
  3. Ignarro LJ et al. (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170: 839–843 · DOI · Paper page
  4. Simonsen U et al. (1995) Involvement of nitric oxide in the non-adrenergic non-cholinergic neurotransmission of horse deep penile arteries: role of charybdotoxin-sensitive K(+)-channels. Br J Pharmacol 116: 2582–2590 · DOI
  5. Holmquist F et al. (1991) Effects of nitric oxide synthase inhibitor Ng-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol Scand 143: 299–304 · DOI
  6. Kuthe A et al. (2000) Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur Urol 38: 108–114 · DOI
  7. Uckert S et al. (2001) Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 19: 14–22 · DOI
  8. Andersson KE (2001) Pharmacology of erectile function and dysfunction. Urol Clin North Am 28: 233–247 · DOI
  9. Lin CS et al. (2000) Expression of three isoforms of cGMP binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 268: 628–635 · DOI
  10. Warrington JS et al. (2000) In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 28: 392–397
  11. Montorsi F et al. (1999) Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 53: 1011–1018 · DOI
  12. Krenzelok EP (2000) Sildenafil: clinical toxicology profile. J Toxicol Clin Toxicol 38: 645–651 · DOI
  13. Milligan PA et al. (2002) A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 53 (Suppl 1): 45S–S52 · DOI
  14. Saenz de Tejada I et al. (2001) The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 13: 282–290 · DOI
  15. Gbekor E et al. (2002) Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol 1 (Suppl 1): 63 · DOI
  16. Stark S et al. (2001) Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 40: 181–188 · DOI
  17. Rajagopalan P et al. (2003) Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 43: 260–267 · DOI · Paper page
  18. Klotz T et al. (2002) Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20mg, a selective PDE5 inhibitor for the treatment of erectile dysfunction. Pharmacotherapy 22: 418
  19. Patterson B et al. (2001) The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 13 (Suppl 5): S43
  20. Ring BJ et al. (2005) Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin Pharmacol Ther 77: 63–75 · DOI
  21. Ashton AK and Bennet RG (1991) Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 60: 194–195 · DOI
  22. Nurnberg HG et al. (1999) Sildenafil for iatrogenic serotoninergic antidepressant medication-induced sexual dysfunction in 4 patients. J Clin Psychiatry 60: 33–35 · DOI
  23. Rosenberg KP (1999) Sildenafil citrate for SSRI-induced sexual side effects. Am J Psychiatry 156: 157 · DOI
  24. Meuleman E et al. (2001) A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 87: 75–81 · DOI
  25. Carson CC et al. (2002) The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 60 (Suppl 2): 12–27 · DOI
  26. Moore RA et al. (2002) Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2: 6 · DOI
  27. Fink HA et al. (2002) Sildenafil for male erectile dysfunction. A systematic review and meta-analysis. Arch Intern Med 162: 1349–1360 · DOI
  28. Rendell MS et al. (1999) Sildenafil for the treatment of erectile dysfunction in men with diabetes. JAMA 281: 421–426 · DOI
  29. Hirsch IB et al. (1999) Viagra® (sildenafil citrate): efficacy and safety in the treatment of erectile dysfunction (ED) in men with diabetes. American Diabetes Association Meeting, 19–22 June, 1999, San Diego, CA, USA.
  30. Stuckey B et al. (2003) Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes mellitus. Results of a randomised controlled trial. Diabetes Care 26: 279–284 · DOI
  31. Boulton AJ et al. (2001) Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 44: 1296–1301 · DOI
  32. Zippe CD et al. (1998) Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 52: 963–596 · DOI
  33. Zippe CD et al. (1999) Sildenafil citrate (Viagra) after radical retropubic prostatectomy: pro. Urology 54: 583–586 · DOI
  34. Nehra A and Goldstein I (1999) Sildenafil citrate (Viagra) after radical retropubic prostatectomy: con. Urology 54: 587–589 · DOI
  35. Lowentritt BH (2000) Sildenafil citrate after radical retropubic prostatectomy. Urology 55: 241–245 · DOI
  36. Zippe CD et al. (2000) Role of Viagra after radical prostatectomy. Urology 55: 241–245 · DOI
  37. Martinez-Jabaloyas JM et al. (2001) Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 40: 641–646 · DOI
  38. Padma-Nathan E et al. (2003) Postoperative nightly administration of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy. J Urol 4 (Suppl): 375
  39. Arruda-Olson AM et al. (2002) Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 287: 719–725 · DOI
  40. Zusman RM et al. (1999) Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 83: 35C–44C · DOI
  41. Hellstrom WJ et al. (2002) Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 23: 763–771 · DOI · Paper page
  42. Porst H et al. (2001) The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 13: 192–199 · DOI
  43. Potempa A-J et al. (2004) Efficacy of vardenafil in men with erectile dysfunction: A flexible dose community practice study. Eur Urol 46: 73–79 · DOI
  44. Goldstein I et al. (2003) Vardenafil, a new phosphodiesterase type 5 inhibitor in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 26: 777–783 · DOI
  45. Brock G et al. (2003) Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 170: 1278–1283 · DOI
  46. Hellstrom WJ et al. (2003) Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 61 (Suppl 1): 8–14 · DOI
  47. Thadani U et al. (2002) The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 40: 2006–2012 · DOI
  48. Padma-Nathan H et al. (2001) Cialis (IC351) provides prompt response and extended period of responsiveness in the treatment of men with erectile dysfunction (ED). J Urol 165 (Suppl): A923
  49. Padma-Nathan H et al. (2001) On demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13: 2–9 · DOI
  50. Porst H (2000) Daily IC351 treatment of ED. Int J Impot Res 12 (Suppl 3): S76 A–B13
  51. Carson C et al. (2005) Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 65: 353–359 · DOI
  52. Brock GB et al. (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168: 1332–1336 · DOI · Paper page
  53. Saenz de Tejada I et al. (2002) Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 25: 2159–2164 · DOI · Paper page
  54. Rosen RC et al. (2002) The international index of erectile function (IIEF): a state-of-the-science review. Int J Impot Res 14: 226–244 · DOI · Paper page
  55. Montorsi F et al. (2004) Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy: a randomized, double-blind, placebo-controlled trial. J Urol 172: 1036–1041 · DOI · Paper page
  56. Porst H (2002) Ic351 (tadalafil, cialis): update on clinical experience. Int J Impot Res 14 (Suppl 1): S57–S64 · DOI
  57. Kloner RA et al. (2003) Cardiovascular effects of tadalafil in patients on common antihypertensive therapy. Am J Cardiology 92 (Suppl 1): 47–57 · DOI
  58. Kloner RA et al. (2003) Time course of the interaction between Tadalafil and Nitrates. J Am Coll Cardiol 42: 1885–1860 · DOI
  59. Hellstrom WJ et al. (2003) Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 170: 887–891 · DOI · Paper page
  60. Keating GM and Scott LJ (2003) Vardenafil: a review of its use in erectile dysfunction. Drugs 63: 2673–2703 · DOI
  61. Ballard SA et al. (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159: 2164–2171 · DOI · Paper page
  62. Klotz T et al. (2001) Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 19: 32–39 · DOI

Cited by

See all 37

Metadata

Authors
Briganti, A., Salonia, A., Gallina, A., Saccà, A., Montorsi, P., Rigatti, P., & Montorsi, F.
Venue
Nature Clinical Practice Urology
Publisher
Springer Science and Business Media LLC
Published
2005-05
Volume
2
Issue
5
Pages
239-247
ISSN
  • 1743-4270
  • 1743-4289
DOI
10.1038/ncpuro0186
Cited by
37
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.